Last updated: February 25, 2026
What is the Drug NDC 83324-0120?
The National Drug Code (NDC) 83324-0120 corresponds to Voretigene neparvovec-rzyl (Luxturna), a gene therapy approved by the U.S. Food and Drug Administration (FDA) in December 2017. It is indicated for inherited retinal disease caused by mutations in the RPE65 gene.
Market Overview
Indication and Patient Population
- Target Population: Patients with confirmed RPE65 mutation-associated retinal dystrophy
- Prevalence: Estimated at 1,000 to 2,000 U.S. patients with confirmed RPE65 mutations.
- Market Potential: Limited but growing, owing to diagnostic advances and increased mutation testing.
Competitive Landscape
- Current Market Entry: Luxturna remains the only FDA-approved gene therapy for this indication.
- Alternatives and Off-label Uses: No direct rival therapies; off-label use of other ocular treatments exists but lacks comparable efficacy.
Regulator and Payer Environment
- Pricing History: Luxturna launched at a list price of approximately $850,000 per eye.
- Reimbursement: Insurance coverage varies; payers demand evidence of genetic confirmation and clinical efficacy.
Cost Structure and Pricing Details
Pricing History and Projection
| Year |
Price per Treatment |
Notes |
| 2017 |
$850,000 |
Launch price for one eye; most patients treated bilaterally, double cost for both eyes |
| 2020 |
Stable |
No significant price change, but some discounts or rebates reported |
| 2023 |
Estimated |
Potential price stabilization with negotiations |
Price Drivers
- Manufacturing complexity: One-time, personalized gene therapy production with high costs.
- Market size: Small patient pool, high price to recoup R&D investment.
- Reimbursement policies: Payers require outcome-based agreements, influencing net pricing.
Market Penetration and Adoption
Adoption Rate
- Uptake: Approximately 1,200 to 1,500 patients treated globally within five years post-launch.
- Geography: Predominantly U.S., with limited rollout in Europe and Canada.
Future Adoption Trends
- Improved diagnostics increase identified candidates.
- Expanding approval in other rare retinal diseases could elevate market size.
Price Projection Scenarios for 2024–2028
Conservative Scenario
- Maintain current price of $850,000 per eye.
- Slight discounts or rebates reduce net price by 10-15%.
- Market saturation around 2,000 patients globally.
Moderate Scenario
- Price slightly reduced to $800,000 per eye due to negotiations and increased competition.
- Market expands to include new indications or older populations.
- Annual treatment volume stabilizes at 400–500 patients.
Aggressive Scenario
- Price drops to $700,000 per eye due to biosimilar competition or new entrants.
- Significant expansion of indications.
- Market penetration accelerates, with 700–1,000 patients annually.
Key Factors Impacting Price and Market Dynamics
- Diagnostic accuracy and genetic testing coverage.
- Long-term clinical outcomes data.
- Policy developments favoring gene therapies.
- Introduction of biosimilars or alternative gene therapies.
Summary
The current price for NDC 83324-0120 remains around $850,000 per eye, reflecting high manufacturing costs and small patient population. Market growth depends on diagnostic expansion and regulatory approvals for broader indications. Price reductions are expected due to negotiations, payer pressure, or competition, with a potential decrease to approximately $700,000–$800,000 per eye by 2028.
Key Takeaways
- The drug has a stable, high price point driven by manufacturing complexity and limited patient pool.
- Market growth hinges on diagnostic advances and expanded indications.
- Price projections suggest potential declines due to negotiations and competitive pressures.
- The total addressable market may grow as awareness and testing increase.
- Reimbursement strategies and outcome-based pricing remain critical to market access.
FAQs
1. How does Luxturna's pricing compare to similar gene therapies?
Luxturna's $850,000 per eye price is among the higher-end for gene therapies, reflecting its specialized manufacturing process and small patient population. Therapies like Zolgensma ($2.1 million for spinal muscular atrophy) have higher prices, but comparison is limited by different indications.
2. What factors could lead to price reductions for NDC 83324-0120?
Introduction of biosimilar gene therapies, negotiated payer discounts, expanded indications reducing per-patient costs, and increased competition could lower net prices.
3. How does market size influence pricing?
A small patient population results in high per-treatment prices to recover R&D investments. Larger markets tend to enable lower prices through volume.
4. What is the outlook for expanding the indications of Luxturna?
Regulatory trials are ongoing for other inherited retinal diseases, which could increase the target population and influence pricing and market size.
5. How might reimbursement policies evolve?
Outcome-based agreements and value-based pricing models are growing trends, potentially affecting net treatment costs and access.
References
[1] U.S. Food and Drug Administration. (2017). FDA approves treatment for patients with inherited blindness. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-patients-inherited-blindness
[2] MarketWatch. (2022). gene therapy market size and forecast. Retrieved from https://www.marketwatch.com
[3] Drugs.com. (2023). Luxturna (Voretigene neparvovec-rzyl) prescribing information. Retrieved from https://www.drugs.com
[4] IQVIA. (2022). Global gene therapy market analysis. Retrieved from https://www.iqvia.com
[5] Lazard. (2021). The pharmaceutical pricing landscape. Retrieved from https://www.lazard.com
